Advertisement

Topics

Effects on Insulin Sensitivity and Body Composition of Combination Therapy With Growth Hormone (GH) and Insulin-like Growth Factor-I (IGF-I)in Growth Hormone Deficient(GHD) and Diabetes and Impaired Glucose Tolerance(IGT)

2014-08-27 03:17:43 | BioPortfolio

Summary

The aim of this study is to measure effects of the combined treatment with GH and IGF-I on glucose sensitivity and body composition in patients with GHD and IGT or diabetes.

Study Design

Allocation: Randomized, Control: Placebo Control, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)

Conditions

Diabetes

Intervention

NutropinAq and Increlex, NutropinAq and placebo

Location

Department of Endocrinology, karolinska University hospital
Solna
Sweden
171 76

Status

Recruiting

Source

Karolinska University Hospital

Results (where available)

View Results

Links

Published on BioPortfolio: 2014-08-27T03:17:43-0400

Clinical Trials [1600 Associated Clinical Trials listed on BioPortfolio]

Study to Define Optimal IGF-1 Monitoring in Children Treated With NutropinAq

The main purpose of this study is to establish an optimal monitoring regimen in NutropinAq treated children, using newly developed capillary blood spot IGF-1 measurement technology.

A Post Marketing Surveillance Program for NutropinAq® in Paediatric Growth Disorders

This study is a multicenter, open label, observational, post marketing surveillance study of NutropinAq® in France, Germany, Italy, Spain and United Kingdom

Transitional Growth Hormone (GH) Use in Growth Hormone Deficient (GHD) Cancer Survivors

Cure rates for childhood malignancies have improved at a remarkable pace.With the increasing cure rate came recognition of the long-term detrimental effects of radiotherapy and chemotherap...

To Compare the Effect of a Subcutaneous Canakinumab Administration to Placebo in Patients With Impaired Glucose Tolerance or Patients With Type 2 Diabetes With Differing Baseline Diabetes Therapies

This is a 10-week placebo-controlled randomized study to investigate the effect of injectable IL-1B antagonist canakinumab in patients with impaired glucose tolerance or Type 2 Diabetes (T...

CARAT: Canagliflozin vs. Placebo for Post Bariatric Patients With Persistent Type 2 Diabetes

This is a prospective, randomized clinical trial for patients with recurrent type 2 diabetes post-gastric bypass surgery that will compare a 6 month course of canagliflozin monotherapy vs....

PubMed Articles [4696 Associated PubMed Articles listed on BioPortfolio]

Effect of a Glucagon Receptor Antibody (REMD-477) in Type 1 Diabetes: A Randomized Controlled Trial.

The aim of the current study was to study the efficacy and safety of REMD-477, a glucagon receptor antagonist, in type 1 diabetes. This was a randomized controlled trial in which 21 patients with type...

Zinc supplementation in pre-diabetes: A randomized double-blind placebo-controlled clinical trial.

To evaluate the effects of Zinc supplementation on glycaemic control, other cadio-metabolic/anthropometric parameters and progression of disease in pre-diabetes.

Weekly glucagon-like peptide-1 receptor agonist albiglutide as monotherapy improves glycemic parameters in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled study.

This phase 3, randomized, double-blind 24-week study with extension to 1 year assessed efficacy and safety of albiglutide compared with placebo in Japanese patients with type 2 diabetes mellitus (T2DM...

Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes.

Background The cardiovascular effects of adding once-weekly treatment with exenatide to usual care in patients with type 2 diabetes are unknown. Methods We randomly assigned patients with type 2 diabe...

Efficacy of metformin on glycemic control and weight in drug-naive type 2 diabetes mellitus patients: A systematic review and meta-analysis of placebo-controlled randomized trials.

Metformin is recommended as the first-line treatment of type 2 diabetes mellitus. Despite its common use, few studies have been conducted to precisely measure the efficacy of metformin versus placebo ...

Medical and Biotech [MESH] Definitions

Urination of a large volume of urine with an increase in urinary frequency, commonly seen in diabetes (DIABETES MELLITUS; DIABETES INSIPIDUS).

The time period before the development of symptomatic diabetes. For example, certain risk factors can be observed in subjects who subsequently develop INSULIN RESISTANCE as in type 2 diabetes (DIABETES MELLITUS, TYPE 2).

A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY.

The state of PREGNANCY in women with DIABETES MELLITUS. This does not include either symptomatic diabetes or GLUCOSE INTOLERANCE induced by pregnancy (DIABETES, GESTATIONAL) which resolves at the end of pregnancy.

Excessive thirst manifested by excessive fluid intake. It is characteristic of many diseases such as DIABETES MELLITUS; DIABETES INSIPIDUS; and NEPHROGENIC DIABETES INSIPIDUS. The condition may be psychogenic in origin.

More From BioPortfolio on "Effects on Insulin Sensitivity and Body Composition of Combination Therapy With Growth Hormone (GH) and Insulin-like Growth Factor-I (IGF-I)in Growth Hormone Deficient(GHD) and Diabetes and Impaired Glucose Tolerance(IGT)"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Alzheimer's Disease
Of all the types of Dementia, Alzheimer's disease is the most common, affecting around 465,000 people in the UK. Neurons in the brain die, becuase  'plaques' and 'tangles' (mis-folded proteins) form in the brain. People with Al...


Searches Linking to this Trial